CompanyVBIONasdaqSan Antonio, TX

Valion Bio, Inc.

Valion Bio develops biologics that activate innate immune pathways for cytoprotection and immune modulation.

SEC EDGAR ClinicalTrials.gov valionbio.com

8-KOct 1Latest SEC filing

Sep 23Latest story

September 2026

Valion Bio names Dean Zikria interim CEO, shifts board leadership

Sep 23PeopleValion Bio, Inc.

Valion Bio names Lisa Wolf president and COO, adds two directors

Sep 1PeopleValion Bio, Inc.

August 2026

Valion Bio expects $1.5 million preferred stock closing with 3i, LP on Aug. 17

Aug 17FinancingValion Bio, Inc.

Valion Bio clears first Entolimod milestone, settles $750,000 payment in preferred stock

Aug 6PartnershipValion Bio, Inc.

July 2026

Valion Bio files S-1 for offering of up to 29.4 million shares and warrants

Jul 17FinancingValion Bio, Inc.